Andere Sprachen Oragenics, Inc.

Aktien

A3D386

US6840235005

OGEN

Markt geschlossen - Nyse Andere Börsenplätze 22:10:00 24.05.2024			% 5 Tage	% 1. Jan.
2,22 ^USD	+1,83 %		-4,72 %	-60,54 %

16.05.	Sektor-Update: Aktien des Gesundheitswesens geben am Donnerstagnachmittag nach	MT
16.05.	Oragenics startet Phase 2-Studie zur Behandlung von Gehirnerschütterungen -- Aktien steigen	MT

Andere Sprachen

Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!

100% kostenlose Registrierung

Oragenics : Shareholder Meeting - Form 8-K	23.05.
Oragenics Appoints William “Frank” Peacock MD as Chief Clinical Officer	22.05.
Oragenics, Inc. to Host Webinar Panel on Neurotrauma Medicine	20.05.
Oragenics, Inc. to Host Webinar Panel on Neurotrauma Medicine	17.05.
Sector Update: Health Care Stocks Ease Thursday Afternoon	16.05.
Oragenics to Start Phase 2 Concussion Treatment Drug Trial -- Shares Rise	16.05.
Oragenics, Inc. Prepares Intranasal Pharmaceutical, ONP-002, for Phase II Concussion Trial	16.05.
Oragenics, Inc. Prepares Intranasal Pharmaceutical, ONP-002, for Phase II Concussion Trial	16.05.
Oragenics: Q1 Earnings Snapshot	15.05.
Oragenics Partners with Avance Clinical for Phase II Concussion Trial in Australia	07.05.
Oragenics, Inc. Announces Partnership with Avance Clinical to Conduct Phase II Clinical Trial in Australia	07.05.
Oragenics, Inc. Announces Notification of Noncompliance with Additional NYSE American Continued Listing Standards	19.04.
North American Morning Briefing : Big Banks Kick -2-	12.04.
Oragenics, Inc. Files 10K and Provides Company Update	01.04.
Oragenics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	29.03.
Oragenics Appoints James Kelly MD, Chief Medical Officer, to Lead Phase II Clinical Trials for Treating Concussion	18.03.
Oragenics Appoints James Kelly MD as Chief Medical Officer, to Lead Phase II Clinical Trials for Treating Concussion	18.03.
Oragenics, Inc. Prepares Drug for Phase II Clinical Trials to Treat Concussion	05.03.
Oragenics, Inc. Prepares Drug for Phase II Clinical Trials to Treat Concussion	05.03.
Oragenics Announces Closing of Public Offering	04.03.

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen Oragenics, Inc.

Aktien

A3D386

US6840235005

OGEN

Andere Sprachen

Filter